The hepatitis C virus (HCV) can cause both acute and chronic hepatitis. The acute process rarely causes hepatic failure, but usually leads to chronic infection. In contrast, chronic HCV infection clearly linked to advanced liver disease, hepatocellular carcinoma (HCC), and has become the leading indication for liver transplantation. Treatment of chronic HCV is aimed at slowing disease progression, preventing complications of cirrhosis, reducing the risk of HCC, and treating extrahepatic complications of the virus. The natural history of hepatitis C is quite variable. Up to 85% of patients with acute HCV eventually progress to chronic infection. Of them, 15-20% of patients will develop cirrhosis within 15-20 years.1 Candidacy for therapy of hepatitis C includes persons who are 18 years of age or older, are willing to be treated, and do not have contraindications to treatment if they have detectable HCV RNA in serum and evidence of chronic hepatitis suggested by elevated serum alanine aminotransferase levels or the presence of considerable necroinflammatory activity and fibrosis on liver biopsy. At present, the recommended therapy for chronic hepatitis C is a combination of formulations of interferon alfa and ribavirin (RBV).2 Interferon alfa is a cytokine that has an important function in the innate antiviral immune response.3 It acts by attaching to cell-surface receptors that signal through the system of Janus-activated kinase and signal transducers and activators of transcription, leading to induction of multiple interferon-stimulated genes.4 These genes include double-stranded RNases, inhibitors of viral protein translation, and proteins that destabilize viral messenger RNA. Interferon alfa also induces the expression of genes involved in the immune response, resulting in activation of natural killer cells, maturation of dendritic cells, proliferation of memory T cells, and prevention of T-cell apoptosis.5 Ribavirin is an oral nucleoside analogue with broad activity against viral pathogens.3 Its mechanism of action against HCV is not completely clear. Ribavirin appears to have minimal direct activity against HCV replication,6 but it may lead to rapid and lethal mutation of virions or depletions of intracellular guanosine triphosphate, which is necessary for viral RNA synthesis.7,8 Ribavirin also has immuno modulatory effects. Definitions of response to treatment are: rapid virological response (RVR) is defined as non-detectability of serum HCV RNA (<50 IU/mL) after 4 weeks of therapy, early virological response (EVR) is defined as undetectable HCV RNA (<50 IU/mL) or at least a 2 log decrease in serum HCV RNA from baseline level after 12 weeks of therapy, end-of-treatment virological response (ETVR) is indicated by non-detectability of HCV RNA at the end of therapy, sustained virological response (SVR) is defined as undetectable serum HCV RNA (<50 IU/mL) 24 weeks after the end of therapy. SVR has been shown to have the following beneficial effects: (i) fibrotic regression; (ii) substantially reduced rate of HCC; (iii) decreased rate of other complications, including liver failure and liver-related death; and (iv) improved quality of life. The most recent important advance in the treatment of hepatitis C was the development of a long-acting interferon, pegylated interferon (peginterferon), produced by the covalent attachment of polyethylene glycol to the interferon molecule. With its increased half-life, peginterferon can be given as a weekly dose.10 Two peginterferon formulations are currently approved for the treatment of hepatitis C: alfa-2a (Pegasys, Roche) and alfa-2b (Peg-Intron, Schering-Plough). In two large trials of these agents, the rates of sustained virologic response to a 48-week course of peginterferon and ribavirin were 54 and 56%, as compared with 44 and 47% with standard interferon and ribavirin and only 29% with peginterferon alone.11,12 Response rates were higher among patients with genotype 2 or 3 than among those with genotype 1. A subsequent trial of different regimens of peginterferon alfa-2a and ribavirin showed that patients with genotype 2 or 3 could be treated with a lower dose of ribavirin (800 mg rather than 1000 to 1200 mg daily) and that the rates of sustained virologic response after 24 weeks of therapy (81 and 84%) were similar to the rates after 48 weeks of therapy (79 and 80%).13 The following have been shown to influence treatment outcome: (i) age; (ii) sex; (iii) virus genotype; (iv) virus load; and (v) stage of fibrosis, especially F3, F4. There are few absolute contraindications for use of peg-IFN-a and ribavirin. They include- present or
past psychosis or severe depression, uncontrolled seizures, hepatic decompensation, pregnancy (RBV), renal failure (RBV), severe heart disease (RBV). The relative contraindications for IFN and ribavirin are history of depression, uncontrolled diabetes mellitus, uncontrolled hypertension, retinopathy, psoriasis, autoimmune thyroiditis or other active autoimmune disorders including autoimmune hepatitis, symptomatic heart disease or severe vascular disease (RBV), anemia/ischemic vascular disease (RBV). In addition to these contraindications special caution is required if IFN is administered in the circumstances like neutropenia (neutrophil count <1,500 cells/cmm), thrombocytopenia (platelet count <85,000/cmm), organ transplantation, history of autoimmune disease, age older than 65 years. Side-effects related to IFN include: cytopenia, abnormalities of thyroid function, depression, irritability, concentration and memory disturbances, visual disturbances, fatigue, muscle aches, headaches, nausea and vomiting, loss of appetite and weight, low grade fever and skin irritation, insomnia, hearing loss, tinnitus, interstitial fibrosis and hair thinning. Side-effects associated with ribavirin include hemolytic anemia, fatigue, itching, rash, cough, gastrointestinal upset, pharyngitis, gout and birth defects. Serious side effects of combination therapy occur in 1 to 2% of patients, and permanent injury and death can occur. There are several areas of uncertainty in the treatment of hepatitis C like use in children, patients >65 years and/or with significant comorbidities, body mass index >30 and hepatic steatosis, persistently normal serum ALT, acute hepatitis C, patients with minimal histologic evidence of liver disease, genotype 4-6 infections, decompensated cirrhosis, failed to respond or have relapsed with prior HCV therapy, substance abuse disorders including alcoholics, HIV/HCV coinfection, renal disease including haemodialysis, history of solid organ transplantation.

Efforts have been made to develop new molecules for better treatment outcomes. Potential targets and approaches in the next 5 years are on long acting IFN, direct antiviral agents like polymerase and protease inhibitors, ribavirin analogues, immunomodulators and therapeutic vaccines. Peginterferon alpha and ribavirin represents the best current treatment available. Major limitations are cost and sensible side-effects. However SVR rates are promising that can even ensure hepatitis C a curable disease.

Professor Mobin Khan, Chairman, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, E-mail: mobin@bdonline.com
Dr. Md. Golam Azam, MBBS, MD, Hepatologist and Senior Researcher, BIRDEM Hospital, Dhaka, E-mail: birdem_azam@yahoo.com

(J Bangladesh Coll Phys Surg 2008; 26: 1-2)

References: